Lexaria reduces at-the-market equity facility from $20M to $5M

Lexaria Bioscience Corp.

Amended Capital on Demand Sales Agreement with JonesTrading; maximum aggregate principal amount reduced to $5M from $20M.
Shares sold under new registration statement on Form S-3 (333-284407), effective Jan 30, 2025.
Agent commission remains 3.0% of gross sales price; customary indemnification and expense reimbursement.
Offering terminates upon sale of all Shares or termination of agreement by either party.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.